14 research outputs found
Novel tissue engineering strategies for cardiac repair after a Myocardial Infarction
In this PhD thesis, we aimed at applying a powerful therapeutic tool, namely tissue engineering and drug delivery systems (microparticles (MPs), nanoparticles (NPs) and hydrogels), to bring significant improvements to the main cause of mortality and morbidity worldwide, i.e. myocardial infarction (MI)
Novel tissue engineering strategies for cardiac repair after a Myocardial Infarction
In this PhD thesis, we aimed at applying a powerful therapeutic tool, namely tissue engineering and drug delivery systems (microparticles (MPs), nanoparticles (NPs) and hydrogels), to bring significant improvements to the main cause of mortality and morbidity worldwide, i.e. myocardial infarction (MI)
Isolation methods of large and small extracellular vesicles derived from cardiovascular progenitors: A comparative study
Since the discovery of the beneficial therapeutical effects of extracellular vesicles (EVs), these agents have been attracting great interest as next-generation therapies. EVs are nanosized membrane bodies secreted by all types of cells that mediate cell–cell communication. Although the classification of different subpopulations of EVs can be complex, they are broadly divided into microvesicles and exosomes based on their biogenesis and in large and small EVs based on their size. As this is an emerging field, current investigations are focused on basic aspects such as the more convenient method for EV isolation. In the present paper, we used cardiac progenitor cells (CPCs) to study and compare different cell culture conditions for EV isolation as well as two of the most commonly employed purification methods: ultracentrifugation (UC) and size-exclusion chromatography (SEC). Large and small EVs were separately analysed. We found that serum starvation of cells during the EV collecting period led to a dramatic decrease in EV secretion and major cell death. Regarding the isolation method, our findings suggest that UC and SEC gave similar EV recovery rates. Separation of large and small EV-enriched subpopulations was efficiently achieved with both purification protocols although certain difference in sample heterogeneity was observed. Noteworthy, while calnexin was abundant in large EVs, ALIX and CD63 were mainly found in small EVs. Finally, when the functionality of EVs was assessed on primary culture of adult murine cardiac fibroblasts, we found that EVs were taken up by these cells, which resulted in a pronounced reduction in the proliferative and migratory capacity of the cells. Specifically, a tendency towards a larger effect of SEC-related EVs was observed. No differences could be found between large and small EVs. Altogether, these results contribute to establish the basis for the use of EVs as therapeutic platforms, in particular in regenerative fields
Isolation methods of large and small extracellular vesicles derived from cardiovascular progenitors: A comparative study
Since the discovery of the beneficial therapeutical effects of extracellular vesicles (EVs), these agents have been attracting great interest as next-generation therapies. EVs are nanosized membrane bodies secreted by all types of cells that mediate cell–cell communication. Although the classification of different subpopulations of EVs can be complex, they are broadly divided into microvesicles and exosomes based on their biogenesis and in large and small EVs based on their size. As this is an emerging field, current investigations are focused on basic aspects such as the more convenient method for EV isolation. In the present paper, we used cardiac progenitor cells (CPCs) to study and compare different cell culture conditions for EV isolation as well as two of the most commonly employed purification methods: ultracentrifugation (UC) and size-exclusion chromatography (SEC). Large and small EVs were separately analysed. We found that serum starvation of cells during the EV collecting period led to a dramatic decrease in EV secretion and major cell death. Regarding the isolation method, our findings suggest that UC and SEC gave similar EV recovery rates. Separation of large and small EV-enriched subpopulations was efficiently achieved with both purification protocols although certain difference in sample heterogeneity was observed. Noteworthy, while calnexin was abundant in large EVs, ALIX and CD63 were mainly found in small EVs. Finally, when the functionality of EVs was assessed on primary culture of adult murine cardiac fibroblasts, we found that EVs were taken up by these cells, which resulted in a pronounced reduction in the proliferative and migratory capacity of the cells. Specifically, a tendency towards a larger effect of SEC-related EVs was observed. No differences could be found between large and small EVs. Altogether, these results contribute to establish the basis for the use of EVs as therapeutic platforms, in particular in regenerative fields
Extracellular vesicle-based therapeutics for heart repair
Extracellular vesicles (EVs) are constituted by a group of heterogeneous membrane vesicles secreted by most cell types that play a crucial role in cell-cell communication. In recent years, EVs have been postulated as a relevant novel therapeutic option for cardiovascular diseases, including myocardial infarction (MI), partially outperforming cell therapy. EVs may present several desirable features, such as no tumorigenicity, low immunogenic potential, high stability, and fine cardiac reparative efficacy. Furthermore, the natural origin of EVs makes them exceptional vehicles for drug delivery. EVs may overcome many of the limitations associated with current drug delivery systems (DDS), as they can travel long distances in body fluids, cross biological barriers, and deliver their cargo to recipient cells, among others. Here, we provide an overview of the most recent discoveries regarding the therapeutic potential of EVs for addressing cardiac damage after MI. In addition, we review the use of bioengineered EVs for targeted cardiac delivery and present some recent advances for exploiting EVs as DDS. Finally, we also discuss some of the most crucial aspects that should be addressed before a widespread translation to the clinical arena
Long-Term Engraftment of Human Cardiomyocytes Combined with Biodegradable Microparticles Induces Heart Repair
Cardiomyocytes derived from human induced pluripotent stem
cells (hiPSC-CMs) are a promising cell source for cardiac repair
after myocardial infarction (MI) because they offer several
advantages such as potential to remuscularize infarcted tissue,
integration in the host myocardium, and paracrine therapeutic
effects. However, cell delivery issues have limited their potential application in clinical practice, showing poor survival and
engraftment after transplantation. In this work, we hypothesized that the combination of hiPSC-CMs with microparticles
(MPs) could enhance long-term cell survival and retention in the
heart and consequently improve cardiac repair. CMs were
obtained by differentiation of hiPSCs by small-molecule manipulation of the Wnt pathway and adhered to biomimetic
poly(lactic-co-glycolic acid) MPs covered with collagen and
poly(D-lysine). The potential of the system to support cell
survival was analyzed in vitro, demonstrating a 1.70-fold and
1.99-fold increase in cell survival after 1 and 4 days, respectively. The efficacy of the system was tested in a mouse MI
model. Interestingly, 2 months after administration, transplanted
hiPSC-CMs could be detected in the peri-infarct area. These cells
not only maintained the cardiac phenotype but also showed
in vivo maturation and signs of electrical coupling. Importantly,
cardiac function was significantly improved, which could be
attributed to a paracrine effect of cells. These findings suggest
that MPs represent an excellent platform for cell delivery in the
field of cardiac repair, which could also be translated into an
enhancement of the potential of cell-based therapies in other
medical applications
Delivery of cardiovascular progenitors with biomimetic microcarriers reduces adverse ventricular remodeling in a rat model of chronic myocardial infarction
Despite tremendous progress in cell-based therapies for heart repair, many challenges still exist. To en-
hance the therapeutic potential of cell therapy one approach is the combination of cells with biomaterial
delivery vehicles. Here, we developed a biomimetic and biodegradable micro-platform based on polymeric
microparticles (MPs) capable of maximizing the therapeutic potential of cardiac progenitor cells (CPCs) and
explored its efficacy in a rat model of chronic myocardial infarction. The transplantation of CPCs adhered
to MPs within the infarcted myocardial microenvironment improved the long-term engraftment of trans-
planted cells for up to one month. Furthermore, the enhancement of cardiac cellular retention correlated
with an increase in functional recovery. In consonance, better tissue remodeling and vasculogenesis were
observed in the animals treated with cells attached to MPs, which presented smaller infarct size, thicker
right ventricular free wall, fewer deposition of periostin and greater density of vessels than animals treated
with CPCs alone. Finally, we were able to show that part of this beneficial effect was mediated by CPC-
derived extracellular vesicles (EVs). Taken together, these findings indicate that the biomimetic microcarri-
ers support stem cell survival and increase cardiac function in chronic myocardial infarction through mod-
ulation of cardiac remodeling, vasculogenesis and CPCs-EVs mediated therapeutic effects. The biomimetic
microcarriers provide a solution for biomaterial-assisted CPC delivery to the heart
Delivery of cardiovascular progenitors with biomimetic microcarriers reduces adverse ventricular remodeling in a rat model of chronic myocardial infarction
Despite tremendous progress in cell-based therapies for heart repair, many challenges still exist. To en-
hance the therapeutic potential of cell therapy one approach is the combination of cells with biomaterial
delivery vehicles. Here, we developed a biomimetic and biodegradable micro-platform based on polymeric
microparticles (MPs) capable of maximizing the therapeutic potential of cardiac progenitor cells (CPCs) and
explored its efficacy in a rat model of chronic myocardial infarction. The transplantation of CPCs adhered
to MPs within the infarcted myocardial microenvironment improved the long-term engraftment of trans-
planted cells for up to one month. Furthermore, the enhancement of cardiac cellular retention correlated
with an increase in functional recovery. In consonance, better tissue remodeling and vasculogenesis were
observed in the animals treated with cells attached to MPs, which presented smaller infarct size, thicker
right ventricular free wall, fewer deposition of periostin and greater density of vessels than animals treated
with CPCs alone. Finally, we were able to show that part of this beneficial effect was mediated by CPC-
derived extracellular vesicles (EVs). Taken together, these findings indicate that the biomimetic microcarri-
ers support stem cell survival and increase cardiac function in chronic myocardial infarction through mod-
ulation of cardiac remodeling, vasculogenesis and CPCs-EVs mediated therapeutic effects. The biomimetic
microcarriers provide a solution for biomaterial-assisted CPC delivery to the heart